Endorectal Epinephrine Suspension May Protect Against Radiation Proctitis During Radiation Therapy for Pelvic Tumor

S. Qin,X. S. Gao,H. Z. Li,C. X. Liu,D. L. Hou,W. D. Nian,X. Y. Li

DOI: https://doi.org/10.1016/j.ijrobp.2016.06.1059

2016-01-01

Abstract:To evaluate the radio-protective efficacy and safety of intra-rectal epinephrine suspension in radiation proctitis in patients receiving radiation therapy (RT) to the pelvis. A total of 50 patients with pelvic carcinoma including prostate cancer, cervical cancer and endometrial carcinoma were randomized to receive epinephrine (n = 24) or sterile physiological saline (n = 26) as intra-rectal suspension before daily radiation therapy. Epinephrine (1:10000, 40ml) was administered intra-rectally for experimental group, and the equivalent volume saline as placebo for control group. All patients should evacuate rectum after irradiation. Toxicity was assessed at baseline, during treatment, and at follow-up visits by using RTOG toxicity scoring criteria. Median follow-up was 39 months (range, 33-44months) for both groups. Five weeks after the start of RT, the incidence of ≥ Grade 2 toxicity was 9.1% in epinephrine group compared with 26.9% in the saline group and was statistical significant (P = 0.016). The onset time of constriction of rectal mucosa vessels was 5±0.8 minutes, the duration was 22.5±2.9 minutes. There were no significant change in blood pressure and heart rate within the period of epinephrine suspension (P = 0.792、0.542). Intra-rectal topical administration of epinephrine is effective in protecting rectum in patients with pelvic tumor undergoing RT, and does not influence blood pressure and heart rate.